Stem definition | Drug id | CAS RN |
---|---|---|
bradycardic agents | 3312 | 155974-00-8 |
Dose | Unit | Route |
---|---|---|
10 | mg | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 4 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.46 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Vd (Volume of distribution) | 1.66 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 10.27 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.28 % | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Sept. 20, 2019 | PMDA | Ono Pharmaceutical Co., Ltd. | |
April 15, 2015 | FDA | AMGEN INC | |
Oct. 25, 2005 | EMA | Les Laboratoires Servier |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Off label use | 470.79 | 17.93 | 454 | 7526 | 471758 | 52869328 |
Photopsia | 149.79 | 17.93 | 46 | 7934 | 4389 | 53336697 |
Drug interaction | 137.07 | 17.93 | 166 | 7814 | 219163 | 53121923 |
Torsade de pointes | 127.59 | 17.93 | 54 | 7926 | 12951 | 53328135 |
Electrocardiogram QT prolonged | 117.85 | 17.93 | 84 | 7896 | 56319 | 53284767 |
Bradycardia | 100.62 | 17.93 | 84 | 7896 | 70972 | 53270114 |
Cardiac failure | 98.46 | 17.93 | 90 | 7890 | 85754 | 53255332 |
First trimester pregnancy | 72.21 | 17.93 | 10 | 7970 | 8 | 53341078 |
Palpitations | 69.53 | 17.93 | 81 | 7899 | 102267 | 53238819 |
Syncope | 63.66 | 17.93 | 81 | 7899 | 111912 | 53229174 |
Ischaemic stroke | 54.99 | 17.93 | 34 | 7946 | 17959 | 53323127 |
Cardiac failure chronic | 54.19 | 17.93 | 21 | 7959 | 4009 | 53337077 |
Crush syndrome | 52.30 | 17.93 | 10 | 7970 | 122 | 53340964 |
Myoglobin blood increased | 48.47 | 17.93 | 15 | 7965 | 1465 | 53339621 |
Ventricular tachycardia | 47.87 | 17.93 | 31 | 7949 | 17731 | 53323355 |
Chest pain | 47.07 | 17.93 | 94 | 7886 | 190091 | 53150995 |
Congestive cardiomyopathy | 45.67 | 17.93 | 21 | 7959 | 6117 | 53334969 |
Apallic syndrome | 45.66 | 17.93 | 12 | 7968 | 651 | 53340435 |
Ventricular fibrillation | 45.48 | 17.93 | 26 | 7954 | 11899 | 53329187 |
Language disorder | 44.71 | 17.93 | 15 | 7965 | 1896 | 53339190 |
Drug effective for unapproved indication | 43.82 | 17.93 | 15 | 7965 | 2015 | 53339071 |
Dizziness | 43.36 | 17.93 | 138 | 7842 | 372121 | 52968965 |
Acute kidney injury | 43.17 | 17.93 | 108 | 7872 | 253760 | 53087326 |
Bundle branch block left | 43.00 | 17.93 | 21 | 7959 | 6992 | 53334094 |
Sensorimotor disorder | 39.08 | 17.93 | 10 | 7970 | 488 | 53340598 |
Pain | 38.67 | 17.93 | 20 | 7960 | 588378 | 52752708 |
Heart rate decreased | 37.05 | 17.93 | 36 | 7944 | 36911 | 53304175 |
Tachycardia | 36.24 | 17.93 | 61 | 7919 | 108151 | 53232935 |
Rheumatoid arthritis | 35.91 | 17.93 | 3 | 7977 | 314528 | 53026558 |
Sinus bradycardia | 35.74 | 17.93 | 24 | 7956 | 14577 | 53326509 |
Dyspnoea | 34.80 | 17.93 | 176 | 7804 | 586056 | 52755030 |
Angina pectoris | 32.64 | 17.93 | 30 | 7950 | 28695 | 53312391 |
Heart rate increased | 32.47 | 17.93 | 50 | 7930 | 82265 | 53258821 |
Pneumobilia | 32.11 | 17.93 | 7 | 7973 | 169 | 53340917 |
Genital rash | 29.26 | 17.93 | 8 | 7972 | 505 | 53340581 |
Hyperparathyroidism secondary | 28.29 | 17.93 | 10 | 7970 | 1477 | 53339609 |
Mitral valve incompetence | 27.39 | 17.93 | 23 | 7957 | 19528 | 53321558 |
Shock haemorrhagic | 27.16 | 17.93 | 17 | 7963 | 9166 | 53331920 |
Drug ineffective | 26.11 | 17.93 | 52 | 7928 | 817193 | 52523893 |
Hyperphosphataemia | 24.70 | 17.93 | 10 | 7970 | 2139 | 53338947 |
Lactic acidosis | 24.44 | 17.93 | 29 | 7951 | 37224 | 53303862 |
Visual impairment | 24.26 | 17.93 | 41 | 7939 | 72871 | 53268215 |
Anaemia folate deficiency | 24.09 | 17.93 | 6 | 7974 | 262 | 53340824 |
Sinus tachycardia | 23.68 | 17.93 | 23 | 7957 | 23549 | 53317537 |
Second trimester pregnancy | 23.42 | 17.93 | 3 | 7977 | 0 | 53341086 |
Third trimester pregnancy | 23.42 | 17.93 | 3 | 7977 | 0 | 53341086 |
Lordosis | 23.13 | 17.93 | 6 | 7974 | 309 | 53340777 |
Hypotension | 22.38 | 17.93 | 86 | 7894 | 253990 | 53087096 |
Tuberculosis of central nervous system | 21.94 | 17.93 | 6 | 7974 | 379 | 53340707 |
Gastrointestinal tract adenoma | 21.92 | 17.93 | 6 | 7974 | 380 | 53340706 |
Femoral neck fracture | 21.04 | 17.93 | 14 | 7966 | 8369 | 53332717 |
Atrial tachycardia | 20.79 | 17.93 | 9 | 7971 | 2275 | 53338811 |
Cardiac arrest | 20.42 | 17.93 | 44 | 7936 | 93623 | 53247463 |
Alopecia | 20.40 | 17.93 | 5 | 7975 | 234578 | 53106508 |
Lupus myocarditis | 20.09 | 17.93 | 4 | 7976 | 61 | 53341025 |
Pneumonia fungal | 20.06 | 17.93 | 11 | 7969 | 4645 | 53336441 |
Orthopnoea | 19.83 | 17.93 | 12 | 7968 | 6092 | 53334994 |
Oliguria | 19.81 | 17.93 | 14 | 7966 | 9224 | 53331862 |
Serotonin syndrome | 19.75 | 17.93 | 22 | 7958 | 26384 | 53314702 |
Osteochondrosis | 19.50 | 17.93 | 7 | 7973 | 1081 | 53340005 |
Sinus arrest | 19.22 | 17.93 | 8 | 7972 | 1836 | 53339250 |
Nasopharyngitis | 19.02 | 17.93 | 3 | 7977 | 192292 | 53148794 |
Gastric antral vascular ectasia | 19.02 | 17.93 | 6 | 7974 | 624 | 53340462 |
Personality disorder | 18.46 | 17.93 | 10 | 7970 | 4121 | 53336965 |
Arrhythmia | 18.37 | 17.93 | 25 | 7955 | 36754 | 53304332 |
Portal hypertensive gastropathy | 18.08 | 17.93 | 6 | 7974 | 733 | 53340353 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Cardiac failure | 255.59 | 18.98 | 201 | 8144 | 91472 | 32413709 |
Bradycardia | 107.57 | 18.98 | 111 | 8234 | 71451 | 32433730 |
Photopsia | 102.12 | 18.98 | 32 | 8313 | 1887 | 32503294 |
Cardiac failure chronic | 87.80 | 18.98 | 41 | 8304 | 7199 | 32497982 |
Hypotension | 84.75 | 18.98 | 177 | 8168 | 215933 | 32289248 |
Computerised tomogram coronary artery abnormal | 78.16 | 18.98 | 16 | 8329 | 158 | 32505023 |
Ischaemic cardiomyopathy | 67.54 | 18.98 | 33 | 8312 | 6401 | 32498780 |
Sinus bradycardia | 60.47 | 18.98 | 39 | 8306 | 12899 | 32492282 |
Dyspnoea | 60.04 | 18.98 | 216 | 8129 | 361829 | 32143352 |
Oesophageal obstruction | 58.36 | 18.98 | 15 | 8330 | 428 | 32504753 |
N-terminal prohormone brain natriuretic peptide increased | 57.15 | 18.98 | 21 | 8324 | 2011 | 32503170 |
Torsade de pointes | 54.68 | 18.98 | 30 | 8315 | 7385 | 32497796 |
Bezoar | 51.67 | 18.98 | 16 | 8329 | 906 | 32504275 |
Angina pectoris | 51.23 | 18.98 | 51 | 8294 | 31375 | 32473806 |
Venous pressure jugular increased | 45.26 | 18.98 | 14 | 8331 | 790 | 32504391 |
Blood pressure systolic decreased | 45.14 | 18.98 | 22 | 8323 | 4241 | 32500940 |
Hyperkalaemia | 42.15 | 18.98 | 69 | 8276 | 69681 | 32435500 |
Base excess decreased | 41.43 | 18.98 | 10 | 8335 | 219 | 32504962 |
Dyspnoea at rest | 40.65 | 18.98 | 19 | 8326 | 3340 | 32501841 |
Acute kidney injury | 40.20 | 18.98 | 165 | 8180 | 293303 | 32211878 |
Drug interaction | 39.28 | 18.98 | 134 | 8211 | 218051 | 32287130 |
Brain natriuretic peptide increased | 39.07 | 18.98 | 20 | 8325 | 4280 | 32500901 |
Blood potassium increased | 38.51 | 18.98 | 33 | 8312 | 16771 | 32488410 |
Oxygen consumption decreased | 38.16 | 18.98 | 9 | 8336 | 178 | 32505003 |
Glomerular filtration rate decreased | 37.46 | 18.98 | 29 | 8316 | 12782 | 32492399 |
Ejection fraction decreased | 37.10 | 18.98 | 33 | 8312 | 17625 | 32487556 |
Ventricular extrasystoles | 36.87 | 18.98 | 28 | 8317 | 11998 | 32493183 |
Venous pressure jugular decreased | 35.74 | 18.98 | 7 | 8338 | 54 | 32505127 |
Dermatitis exfoliative generalised | 34.85 | 18.98 | 17 | 8328 | 3284 | 32501897 |
Ventricular arrhythmia | 33.23 | 18.98 | 19 | 8326 | 5060 | 32500121 |
Sinus arrest | 31.99 | 18.98 | 13 | 8332 | 1631 | 32503550 |
Urticaria chronic | 31.82 | 18.98 | 7 | 8338 | 100 | 32505081 |
Atrial tachycardia | 31.67 | 18.98 | 14 | 8331 | 2163 | 32503018 |
Left ventricular enlargement | 30.91 | 18.98 | 10 | 8335 | 653 | 32504528 |
Death | 29.46 | 18.98 | 33 | 8312 | 382484 | 32122697 |
Oedema peripheral | 28.84 | 18.98 | 79 | 8266 | 114012 | 32391169 |
Electrocardiogram abnormal | 27.98 | 18.98 | 20 | 8325 | 7810 | 32497371 |
Ventricular dysfunction | 27.18 | 18.98 | 15 | 8330 | 3731 | 32501450 |
ECG signs of myocardial ischaemia | 26.90 | 18.98 | 7 | 8338 | 210 | 32504971 |
Asthma-chronic obstructive pulmonary disease overlap syndrome | 26.75 | 18.98 | 10 | 8335 | 1004 | 32504177 |
Blood creatinine increased | 26.75 | 18.98 | 69 | 8276 | 96063 | 32409118 |
Left ventricular dilatation | 26.27 | 18.98 | 9 | 8336 | 702 | 32504479 |
Hypertrophy | 26.24 | 18.98 | 8 | 8337 | 430 | 32504751 |
Presyncope | 26.21 | 18.98 | 27 | 8318 | 17274 | 32487907 |
Tracheal atresia | 24.68 | 18.98 | 4 | 8341 | 8 | 32505173 |
Ventricular fibrillation | 24.41 | 18.98 | 26 | 8319 | 17284 | 32487897 |
Syncope | 24.36 | 18.98 | 64 | 8281 | 90060 | 32415121 |
Cardiomyopathy | 24.27 | 18.98 | 25 | 8320 | 15988 | 32489193 |
Ventricular tachycardia | 23.74 | 18.98 | 31 | 8314 | 25525 | 32479656 |
Mean cell haemoglobin decreased | 23.70 | 18.98 | 10 | 8335 | 1380 | 32503801 |
Tricuspid valve incompetence | 22.84 | 18.98 | 19 | 8326 | 9268 | 32495913 |
Congestive cardiomyopathy | 22.58 | 18.98 | 17 | 8328 | 7185 | 32497996 |
Bronchial hyperreactivity | 22.45 | 18.98 | 10 | 8335 | 1572 | 32503609 |
Large cell lung cancer metastatic | 22.26 | 18.98 | 4 | 8341 | 18 | 32505163 |
Low cardiac output syndrome | 21.99 | 18.98 | 7 | 8338 | 434 | 32504747 |
Blood chloride increased | 21.74 | 18.98 | 12 | 8333 | 2987 | 32502194 |
Pulmonary oedema | 21.73 | 18.98 | 41 | 8304 | 46226 | 32458955 |
Oesophageal haemorrhage | 21.64 | 18.98 | 9 | 8336 | 1198 | 32503983 |
Lichenoid keratosis | 21.35 | 18.98 | 11 | 8334 | 2385 | 32502796 |
Blood luteinising hormone increased | 21.34 | 18.98 | 5 | 8340 | 96 | 32505085 |
Eosinophilia | 21.23 | 18.98 | 29 | 8316 | 24929 | 32480252 |
Heart rate decreased | 21.01 | 18.98 | 29 | 8316 | 25171 | 32480010 |
Contraindicated product administered | 20.68 | 18.98 | 25 | 8320 | 19051 | 32486130 |
Cardiac hypertrophy | 20.50 | 18.98 | 8 | 8337 | 903 | 32504278 |
Diastolic dysfunction | 20.19 | 18.98 | 14 | 8331 | 5210 | 32499971 |
Blood follicle stimulating hormone increased | 19.90 | 18.98 | 5 | 8340 | 130 | 32505051 |
Pulmonary function test abnormal | 19.81 | 18.98 | 10 | 8335 | 2076 | 32503105 |
Carbon dioxide decreased | 19.70 | 18.98 | 9 | 8336 | 1500 | 32503681 |
Off label use | 19.63 | 18.98 | 140 | 8205 | 306180 | 32199001 |
Pancreatitis chronic | 19.14 | 18.98 | 10 | 8335 | 2230 | 32502951 |
Haemodynamic test abnormal | 18.98 | 18.98 | 4 | 8341 | 46 | 32505135 |
Source | Code | Description |
---|---|---|
ATC | C01EB17 | CARDIOVASCULAR SYSTEM CARDIAC THERAPY OTHER CARDIAC PREPARATIONS Other cardiac preparations |
ATC | C07FX05 | CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS, OTHER COMBINATIONS Beta blocking agents, other combinations |
ATC | C07FX06 | CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS, OTHER COMBINATIONS Beta blocking agents, other combinations |
MeSH PA | D002317 | Cardiovascular Agents |
FDA EPC | N0000191544 | Hyperpolarization-activated Cyclic Nucleotide-gated Channel Blocker |
FDA MoA | N0000191546 | Hyperpolarization-activated Cyclic Nucleotide-gated Channel Antagonists |
CHEBI has role | CHEBI:38147 | cardiotonic drugs |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Chronic heart failure | indication | 48447003 | |
Angina pectoris | indication | 194828000 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 8.45 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
EQ 5MG BASE | CORLANOR | AMGEN INC | N206143 | April 15, 2015 | RX | TABLET | ORAL | 7361649 | Feb. 22, 2026 | A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE |
EQ 5MG BASE | CORLANOR | AMGEN INC | N206143 | April 15, 2015 | RX | TABLET | ORAL | 7361650 | Feb. 22, 2026 | A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE |
EQ 5MG BASE | CORLANOR | AMGEN INC | N206143 | April 15, 2015 | RX | TABLET | ORAL | 7879842 | Feb. 22, 2026 | A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE |
EQ 7.5MG BASE | CORLANOR | AMGEN INC | N206143 | April 15, 2015 | RX | TABLET | ORAL | 7361649 | Feb. 22, 2026 | A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE |
EQ 7.5MG BASE | CORLANOR | AMGEN INC | N206143 | April 15, 2015 | RX | TABLET | ORAL | 7361650 | Feb. 22, 2026 | A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE |
EQ 7.5MG BASE | CORLANOR | AMGEN INC | N206143 | April 15, 2015 | RX | TABLET | ORAL | 7879842 | Feb. 22, 2026 | A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE |
5MG/5ML (1MG/ML) | CORLANOR | AMGEN INC | N209964 | April 22, 2019 | RX | SOLUTION | ORAL | 7361649 | Feb. 22, 2026 | A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE |
5MG/5ML (1MG/ML) | CORLANOR | AMGEN INC | N209964 | April 22, 2019 | RX | SOLUTION | ORAL | 7361650 | Feb. 22, 2026 | A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE |
5MG/5ML (1MG/ML) | CORLANOR | AMGEN INC | N209964 | April 22, 2019 | RX | SOLUTION | ORAL | 7879842 | Feb. 22, 2026 | A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE |
EQ 5MG BASE | CORLANOR | AMGEN INC | N206143 | April 15, 2015 | RX | TABLET | ORAL | 7867996 | Dec. 12, 2026 | A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE |
EQ 7.5MG BASE | CORLANOR | AMGEN INC | N206143 | April 15, 2015 | RX | TABLET | ORAL | 7867996 | Dec. 12, 2026 | A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE |
5MG/5ML (1MG/ML) | CORLANOR | AMGEN INC | N209964 | April 22, 2019 | RX | SOLUTION | ORAL | 7867996 | Dec. 12, 2026 | A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
5MG/5ML (1MG/ML) | CORLANOR | AMGEN INC | N209964 | April 22, 2019 | RX | SOLUTION | ORAL | April 22, 2022 | NEW PRODUCT |
5MG/5ML (1MG/ML) | CORLANOR | AMGEN INC | N209964 | April 22, 2019 | RX | SOLUTION | ORAL | Oct. 22, 2022 | PEDIATRIC EXCLUSIVITY |
5MG/5ML (1MG/ML) | CORLANOR | AMGEN INC | N209964 | April 22, 2019 | RX | SOLUTION | ORAL | April 22, 2026 | INDICATED FOR THE TREATMENT OF STABLE SYMPTOMATIC HEART FAILURE DUE TO DILATED CARDIOMYOPATHY (DCM) IN PEDIATRIC PATIENTS AGED 6 MONTHS AND OLDER, WHO ARE IN SINUS RHYTHM WITH AN ELEVATED HEART RATE |
5MG/5ML (1MG/ML) | CORLANOR | AMGEN INC | N209964 | April 22, 2019 | RX | SOLUTION | ORAL | Oct. 22, 2026 | PEDIATRIC EXCLUSIVITY |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 | Ion channel | BLOCKER | IC50 | 5.70 | IUPHAR | DRUG LABEL | |||
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2 | Ion channel | BLOCKER | UNKNOWN | DRUG LABEL | |||||
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 3 | Ion channel | BLOCKER | IC50 | 5.70 | IUPHAR | DRUG LABEL | |||
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 | Ion channel | EC50 | 5.37 | CHEMBL | |||||
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 | Ion channel | EC50 | 5.35 | CHEMBL | |||||
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2 | Ion channel | EC50 | 5.34 | CHEMBL |
ID | Source |
---|---|
D07165 | KEGG_DRUG |
148849-67-6 | SECONDARY_CAS_RN |
4034416 | VANDF |
C0257190 | UMLSCUI |
CHEBI:85969 | CHEBI |
CHEMBL471737 | ChEMBL_ID |
CHEMBL2145077 | ChEMBL_ID |
D000077550 | MESH_DESCRIPTOR_UI |
DB09083 | DRUGBANK_ID |
2357 | IUPHAR_LIGAND_ID |
7523 | INN_ID |
3H48L0LPZQ | UNII |
132999 | PUBCHEM_CID |
1649479 | RXNORM |
20884 | MMSL |
233849 | MMSL |
d05706 | MMSL |
011156 | NDDF |
011157 | NDDF |
420906000 | SNOMEDCT_US |
421228002 | SNOMEDCT_US |
421692002 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Corlanor | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55513-800 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 31 sections |
Corlanor | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55513-810 | TABLET, FILM COATED | 7.50 mg | ORAL | NDA | 31 sections |
Corlanor | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55513-813 | SOLUTION | 5 mg | ORAL | NDA | 31 sections |
Corlanor | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-3309 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 33 sections |